IP Library Granted Patent US 11,045,418
Granted Patent B2
US 11,045,418 · App. 15/554,132 · Granted Jun 29, 2021

Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell

Inventors: Hossam Hefesha (Wiesbaden, DE); Ugur Sahin (Mainz, DE); Heinrich Haas (Mainz, DE); Sebastian Kreiter (Mainz, DE); Yves Hüsemann (Wiesbaden, DE); Mustafa Diken (Mainz, DE); Kerstin Walzer (Darmstadt, DE)
Assignees: BioNTech RNA Pharmaceuticals GmbH; Tron-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
A61K9/1075A61K9/0019A61K9/1272A61K31/663A61K31/675A61K31/7105A61K39/0011A61K39/395A61K45/06A61K47/186A61K47/24A61K48/00A61P35/00A61K2039/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,045,418
App. No.
15/554,132
Granted
Jun 29, 2021
Kind
B2
Abstract

The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.

Claims (12)

1. A method for delivering an antigen to antigen presenting cells in the spleen, or expressing an antigen in antigen presenting cells in the spleen, the method comprising administering to a subject a pharmaceutical composition comprising a lipid particle comprising:

(i) 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) and 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) in a 1:1 molar ratio,

(ii) at least one water-soluble therapeutically effective compound for immunotherapy, and

(iii) RNA encoding at least one antigen;

wherein the pharmaceutical composition is administered intravenously, and wherein the RNA encoding at least one antigen is preferentially expressed in the spleen compared to the liver and lung.

2. The method of claim 1 , wherein the therapeutically effective compound is a γδ T cell-stimulating bisphosphonate.

3. The method of claim 2 wherein the bisphosphonate is an aminobisphosphonate.

4. The method of claim 1 , wherein RNA expression in the spleen is at least 5-fold the amount of RNA expression in the lung and/or liver.

5. The method of claim 3 , wherein the aminobisphosphonate is zoledronic acid.

6. The method of claim 5 , wherein the zoledronic acid concentration in the lipid particle is 0.05 μM to 50.0 μM.

7. The method of claim 1 , wherein the RNA encoding at least one antigen encodes an antigen that is selected from the group consisting of a disease-associated antigen, a tumor antigen, a viral antigen, and a bacterial antigen.

8. The method of claim 1 , wherein the number of positive charges derived from the lipid particle divided by the number of negative charges derived from the RNA is between 0.025 and 4.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Sep 20, 2021
From: BIONTECH RNA PHARMACEUTICALS GMBH; BIONTECH SE
To: BIONTECH SE
Reel/Frame 057715/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: KREITER, SEBASTIAN; DIKEN, MUSTAFA
To: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GGMBH
Reel/Frame 046057/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: HEFESHA, HOSSAM; HAAS, HEINRICH; HUSEMANN, YVES; WALZER, KERSTIN
To: BIONTECH RNA PHARMACEUTICALS GMBH
Reel/Frame 046057/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: SAHIN, UGUR
To: TRON- TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GGMBH; BIONTECH RNA PHARMACEUTICALS GMBH
Reel/Frame 046057/0638 →
Priority Claims (1)
WO PCT/EP2015/057118 · Mar 31, 2015 · international
Continuity (1)
Related Publication 20180263907A1 · Sep 20, 2018
Cited By (2)
US 12,559,450 US 12,605,464